GSK Out Licenses its Tuberculosis Vaccine (M72/AS01E ) to Bill & Melinda Gates Medical Research Institute

 GSK Out Licenses its Tuberculosis Vaccine (M72/AS01E ) to Bill & Melinda Gates Medical Research Institute

GSK Out Licenses its Tuberculosis Vaccine (M72/AS01E ) to Bill & Melinda Gates Medical Research Institute

Shots:

  • GSK has licensed its M72/AS01E to the Gates MRI for further development and potential use of vaccine therapy in low-income countries with high TB burdens
  • Under the agreement, the GATES MRI will lead the development program and will be responsible to sponsor future clinical studies while GSK will provide the AS01 adjuvant for the development program
  • GSK’s M72/AS01E consist of M72 recombinant fusion protein, derived from two Mycobacterium tuberculosis antigens (Mtb32A and Mtb39A), combined with the adjuvant system AS01

Click here ­to­ read full press release/ article | Ref: GSK | Image: Business Standard

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post